Home/Alethio Therapeutics/Rohit Batta, MD

RB

Rohit Batta, MD

Chief Executive Officer

Alethio Therapeutics

Therapeutic Areas

Oncology Hematology

Alethio Therapeutics Pipeline

Drug	Indication	Phase
AT-01 (ATX-011)	Myeloproliferative Neoplasms (MPNs)	Pre-clinical
AT-02	Mutant CALR-driven Myeloproliferative Neoplasms (MPNs)	Pre-clinical

Leadership Team at Alethio Therapeutics

Chair of the Board

Professor Adam Mead

Professor Beth Psaila

View full Alethio Therapeutics profile